(Q39983708)

16 September 2017

title

The anaplastic lymphoma kinase is an effective oncoantigen for lymphoma vaccination (English)

1 reference

16 September 2017

1

Roberto Chiarle

1 reference

16 September 2017

2

Cinzia Martinengo

1 reference

16 September 2017

7

Giorgio Inghirami

1 reference

16 September 2017

4

Chiara Ambrogio

1 reference

16 September 2017

Cristina Mastini

3

1 reference

16 September 2017

Valentina D'Escamard

series ordinal

5

1 reference

16 September 2017

Guido Forni

series ordinal

6

1 reference

16 September 2017

language of work or name

English

0 references

publication date

11 May 2008

1 reference

16 September 2017

1 reference

16 September 2017

volume

14

1 reference

16 September 2017

issue

6

1 reference

16 September 2017

page(s)

676-680

1 reference

https://scigraph.springernature.com/pub.10.1038/nm1769

16 September 2017

exact match

0 references

cites work

Vaccines for tumour prevention

1 reference

7 January 2021

Designer cancer vaccines are still in fashion.

1 reference

7 January 2021

Vaccination strategies for lymphomas

1 reference

7 January 2021

The anaplastic lymphoma kinase in the pathogenesis of cancer

1 reference

7 January 2021

Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer

1 reference

7 January 2021

Expression and functional analysis of the anaplastic lymphoma kinase (ALK) gene in tumor cell lines

1 reference

7 January 2021

Anaplastic lymphoma kinase is expressed in different subtypes of human breast cancer.

1 reference

7 January 2021

Cancer immunotherapy: moving beyond current vaccines

1 reference

7 January 2021

Vaccine strategies to treat lymphoproliferative disorders.

1 reference

7 January 2021

Translocations involving anaplastic lymphoma kinase (ALK).

1 reference

7 January 2021

ALK as a novel lymphoma-associated tumor antigen: identification of 2 HLA-A2.1-restricted CD8+ T-cell epitopes

1 reference

7 January 2021

B and CTL responses to the ALK protein in patients with ALK-positive ALCL

1 reference

7 January 2021

CD4 T-helper responses to the anaplastic lymphoma kinase (ALK) protein in patients with ALK-positive anaplastic large-cell lymphoma

1 reference

7 January 2021

ALK a novel lymphoma-associated tumor antigen for vaccination strategies

1 reference

7 January 2021

Stat3 is required for ALK-mediated lymphomagenesis and provides a possible therapeutic target

1 reference

7 January 2021

Detection of integration of plasmid DNA into host genomic DNA following intramuscular injection and electroporation

1 reference

7 January 2021

The immunogenicity of Bcr-Abl expressing dendritic cells is dependent on the Bcr-Abl kinase activity and dominated by Bcr-Abl regulated antigens

1 reference

7 January 2021

NPM-ALK transgenic mice spontaneously develop T-cell lymphomas and plasma cell tumors.

1 reference

7 January 2021

Cyclin B1 and other cyclins as tumor antigens in immunosurveillance and immunotherapy of cancer

1 reference

7 January 2021

Anaplastic large cell lymphoma in childhood: analysis of 72 patients treated on The United Kingdom Children's Cancer Study Group chemotherapy regimens

1 reference

7 January 2021

DNA vaccines for cancer too.

1 reference

7 January 2021

Granzyme B activity in target cells detects attack by cytotoxic lymphocytes

1 reference

7 January 2021

T-cell non-Hodgkin lymphoma

1 reference

7 January 2021

Characterization of the expression of the ALK receptor tyrosine kinase in mice

1 reference

7 January 2021

Ablation of oncogenic ALK is a viable therapeutic approach for anaplastic large-cell lymphomas

1 reference

7 January 2021

Anaplastic lymphoma kinase activity is essential for the proliferation and survival of anaplastic large-cell lymphoma cells

1 reference

7 January 2021

B cells inhibit induction of T cell-dependent tumor immunity.

1 reference

7 January 2021

Tracing tolerance and immunity in vivo by CFSE-labeling of administered cells

1 reference

7 January 2021

Identifiers

DOI

10.1038/NM1769

1 reference

16 September 2017

1 reference